Neurocrine biosciences initiates phase 2 clinical study evaluating nbi-1117568 in adults with schizophrenia

Nbi-1117568 is an investigational, first-in-class, muscarinic m4 selective agonist san diego , oct. 27, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, today announced the first patient has been randomized for its phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound nbi-1117568 in adults with schizophrenia. nbi-1117568 is an investigational, muscarinic m4 selective acetylcholine receptor agonist believed to be a key regulator of neurotransmitters impacted by schizophrenia.
NBIX Ratings Summary
NBIX Quant Ranking